Krystal Biotech Inc.

AI Score

0

Unlock

183.12
6.95 (3.95%)
At close: Feb 20, 2025, 3:59 PM
185.00
1.03%
After-hours: Feb 20, 2025, 06:00 PM EST

Company Description

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States.

Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa.

The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome.

Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product.

Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.

Krystal Biotech Inc.
Krystal Biotech Inc. logo
Country United States
IPO Date Sep 20, 2017
Industry Biotechnology
Sector Healthcare
Employees 229
CEO Krish S. Krishnan M.B.A., M.S.

Contact Details

Address:
2100 Wharton Street
Pittsburgh, Pennsylvania
United States
Website https://www.krystalbio.com

Stock Details

Ticker Symbol KRYS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001711279
CUSIP Number 501147102
ISIN Number US5011471027
Employer ID 82-1080209
SIC Code 2836

Key Executives

Name Position
Krish S. Krishnan M.B.A., M.S. Founder, Chairman, President & Chief Executive Officer
Christine Wilson Head of U.S. Sales & Marketing
David Chien Senior Vice President of Clinical Development
Dr. Stephane Paquette Ph.D. Vice President of Corporate Development
John Karakkal Vice President of North American Sales & Marketing
John Thomas General Counsel & Corporate Secretary
Josh Suskin Senior Director & Head of US Human Resources
Kathryn A. Romano CPA Executive Vice President & Chief Accounting Officer
Laurent Goux Senior Vice President & GM of Europe
Suma M. Krishnan Founder, President of R&D and Director

Latest SEC Filings

Date Type Title
Feb 19, 2025 8-K Current Report
Feb 19, 2025 10-K Annual Report
Feb 05, 2025 SCHEDULE 13G Filing
Dec 18, 2024 8-K Current Report
Dec 13, 2024 4 Filing
Dec 13, 2024 4 Filing
Dec 12, 2024 8-K Current Report
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 04, 2024 10-Q Quarterly Report